Pearls & Oy-sters: Salt and Pepper Sign, PLNTY for Drug-Resistant Epilepsy

Elma M Paredes-Aragón1, Norah A AlKhaldi2, Jorge G Burneo2

  • 1From the Departments of Clinical Neurological Sciences (E.M.P.-A., J.G.B., D.L., L.C.A., D.S., S.M.M.), Department of Clinical Neurological Sciences and Oncology (M.M), Epidemiology and Biostatistics (J.G.B., D.S.), Pathology and Laboratory Medicine (L.C.A.), Medical Imaging (S.M.M.), Medical Biophysics (S.M.M.), and Psychology (S.M.M.), Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Neurological Emergencies (E.M.P.-A.), National Institute of Neurology and Neurosurgery, Mexico City, Mexico; Department of Neurology (N.A.A.), King Fahad University Hospital, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; and Epilepsy Department (M.H.-A.), Neurology Division, Instituto Nacional de Ciencias Neurológicas, Lima, Peru. elma.paredesaragon@lhsc.on.ca.

Neurology
|December 23, 2022
PubMed

Insights

Drug-resistant epilepsy, often caused by tumors, can be challenging to treat. Polymorphic low-grade neuroepithelial tumor of the young (PLNTY) is a newly identified, highly epileptogenic tumor subtype with distinct genetic and imaging features.

Area of Science:

  • Neurology
  • Neuro-oncology
  • Pathology

Background:

  • Drug-resistant epilepsy affects two-thirds of epilepsy cases.
  • Tumors account for a significant proportion of adult and childhood-onset epilepsies.
  • Traditional tumor classifications for epilepsy are evolving with genetic insights.

Purpose of the Study:

  • To introduce and characterize Polymorphic low-grade neuroepithelial tumor of the young (PLNTY) as a distinct, highly epileptogenic tumor subtype.
  • To highlight the diagnostic challenges and unique features of PLNTY tumors.
  • To differentiate PLNTY from other low-grade gliomas based on pathological and genetic markers.

Main Methods:

  • Review of pathological and genetic findings in epilepsy-associated tumors.
  • Analysis of imaging characteristics, including MRI FLAIR (salt and pepper sign) and CT head calcifications.
  • Immunohistochemical staining for CD34.

Main Results:

  • PLNTY tumors exhibit oligodendroglioma-like cellular components and infiltration patterns.
  • A strong CD34-immunopositive stain is a key diagnostic clue for PLNTY.
  • Characteristic radiologic findings include the 'salt and pepper sign' on MRI FLAIR and calcifications on CT.

Conclusions:

  • PLNTY represents a distinct, highly epileptogenic tumor entity.
  • Integrated pathological, genetic, and radiological analysis is crucial for accurate PLNTY diagnosis.
  • Identification of PLNTY aids in understanding and potentially managing drug-resistant epilepsy cases linked to specific tumor types.

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
242
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
773
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
472
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
241
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
517
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
399